Back

Cardiorenal protective therapy for CKD: Real world data from the Hellenic Cardiorenal Morbidity Snapshots (HECMOS)

30 August 2025 (11:35 - 11:45)
Organised by: Logo
Congress Presentation Part of: Improving pharmacotherapy in primary prevention Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ioannis Leontsinis

Hippokration General Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Lipid management in high cardiovascular risk patients without prior myocardial infarction or stroke - preliminary data from the VESALIUS-REAL global burden study
Doctor Q. Chan (Greater London, GB)
Abstract Slides Video
Presentation thumbnail
Cardiovascular risks of ibuprofen versus naproxen: a target trial emulation
Doctor A. Bech-Drewes (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Lower rate of ischemic events with alirocumab in patients with atherosclerotic cardiovascular disease but without prior acute ischemic events
Professor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
Aspirin for the primary prevention of major adverse cardiovascular events in patients with elevated lipoprotein(a): a meta-analysis
Doctor P. Lee (Bronx, US)
Abstract Slides Video
Presentation thumbnail
Efficacy of inclisiran in patients affected by familial hypercholesterolemia: data from CHOLINET Registry
Doctor C. Cotticelli (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Improving pharmacotherapy in primary prevention
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 11:35 CET
You may be interested in
thumbnail
Congress Presentation
Towards the cure of CKD in T2DM: are we ready to implement four foundational therapies? - pro
thumbnail
Congress Session
Clash of the titans: when cardiovascular and kidney diseases overlap
thumbnail
Congress Session
A new era in the management of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and cardiovascular complications

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources